Pharmaceutical

FDA approves BeiGene’s TEVIMBRA for oesophageal cancer

The US FDA has approved BeiGene's TEVIMBRA for oesophageal squamous cell carcinoma (ESCC) after previous systemic chemotherapy.

Mar 16, 2024 - 00:00
FDA approves BeiGene’s TEVIMBRA for oesophageal cancer
The US FDA has approved BeiGene's TEVIMBRA for oesophageal squamous cell carcinoma (ESCC) after previous systemic chemotherapy.
Read the original article

Tags:

Previous Article

Noramco launches North American pharma supply chain services provider

Next Article

Q&A: Increasing awareness around digital therapeutics key to realising full pote...

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

Gilead and Terray link to develop small-molecule therapies

Gilead and Terray link to develop small-molecule therapies

Dec 19, 2024

STAT+: Maze CEO ‘personally disappointed’ in Sanofi decision to terminate partnership

STAT+: Maze CEO ‘personally disappointed’ in Sanofi dec...

Dec 13, 2023

Reneo cuts 70% of staff following Phase III trial failure

Reneo cuts 70% of staff following Phase III trial failure

Dec 16, 2023